Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
1.01%
)
US TECH 100
24,015.20
(
0.00%
)
Dow Jones
46,946.41
(
0.83%
)
Brent Oil
101.40
(
3.15%
)
Bitcoin
74,233.63
(
-0.82%
)
News Focus
News Focus
Post# of 257250
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 92539

Thursday, 04/08/2010 8:45:19 AM

Thursday, April 08, 2010 8:45:19 AM

Post# of 257250
Presidio to present preclinical NS5A data at EASL:

http://finance.yahoo.com/news/Presidio-Pharmaceuticals-Inc-bw-4263771663.html?x=0&.v=1

This drug candidate, previously unnamed, is now called PPI-461. Presidio acquired the compound from XTL Biopharmaceuticals’ back burner in Mar 2008 (#msg-27791536).

I suspect that Presidio is bringing PPI-461 out of the woodwork now to capitalize on the recent buzz about BMS-790052 (#msg-47876219).


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now